NTRA - Natera, Inc. Stock Analysis | ConvictionStocks
Healthcare
Natera, Inc.
NTRA
$341.79+3.91%
Price is delayed.
Add to watchlist
About Natera, Inc.
Natera runs a laboratory that performs genetic blood tests to help doctors diagnose and monitor diseases. For cancer patients, they offer blood tests that detect cancer cells remaining after treatment or spot early recurrence. For pregnant women, they provide non-invasive prenatal tests that screen for genetic conditions in the fetus using a simple blood sample. They also test for inherited cancer risk, analyze miscarriage tissue to understand pregnancy loss, and monitor organ transplant rejection through blood analysis. Hospitals, clinics, and other laboratories use Natera's tests and send th...
1D1W1M3M1Y5YMAX
Loading chart...
Chart powered by TradingView Lightweight Charts
Members only
Full research is for ConvictionStocks members
Members read the rest of this page. Where we have it for this company, that is:
What each number means, in plain English, with the Wall Street name where the two differ.
A plain-English summary of the company.
How many analysts cover it, and the count behind each rating.